CMRX - Chimerix Stock Price, News & Analysis

$4.53 0.14 (3.19 %)
(As of 11/24/2017 02:40 AM ET)
Previous Close$4.39
Today's Range$4.41 - $4.59
52-Week Range$4.17 - $6.64
Volume116,500 shs
Average Volume299,471 shs
Market Capitalization$206.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About Chimerix (NASDAQ:CMRX)

Chimerix logoChimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMRX
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio16.99%
Quick Ratio16.99%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.70 million
Price / Sales37.46
Cash FlowN/A
Price / CashN/A
Book Value$5.03 per share
Price / Book0.90

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.43)
Net Income$-76,390,000.00
Net Margins-1,440.67%
Return on Equity-26.00%
Return on Assets-25.10%

Miscellaneous

Employees87
Outstanding Shares47,130,000

Frequently Asked Questions for Chimerix (NASDAQ:CMRX)

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.06. The biopharmaceutical company earned $0.90 million during the quarter, compared to analysts' expectations of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. View Chimerix's Earnings History.

Where is Chimerix's stock going? Where will Chimerix's stock price be in 2017?

2 brokerages have issued 1-year price targets for Chimerix's stock. Their predictions range from $6.00 to $7.00. On average, they expect Chimerix's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Chimerix.

What are Wall Street analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:

  • 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (11/13/2017)
  • 2. FBR & Co analysts commented, "We attended Chimerix’s Investor/Analyst Day on April 27 in New York and came away looking forward to further clinical development in 2017 and 2018. Chimerix reported data from the single ascending dose (SAD) study with IV brincidofovir (BCV) and provided additional details on future clinical trials." (5/1/2017)
  • 3. Cowen Inc analysts commented, "CMRX is developing brincidofovir as an inhibitor of several DNA viruses." (4/28/2017)

Who are some of Chimerix's key competitors?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:

  • Ernest B. Mario Ph.D., Independent Chairman of the Board (Age 78)
  • Michelle Berrey M.D., President, Chief Executive Officer, Chief Medical Officer, Director (Age 48)
  • Timothy W. Trost CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary (Age 56)
  • Roy W. Ware Ph.D., Chief Manufacturing and Technology Officer
  • Heather Knight-Trent, Vice President - Regulatory Affairs
  • Randall Lanier Ph.D., Chief Science Officer
  • W. Garrett Nichols M.D., Chief Medical Officer (Age 46)
  • Linda M. Richardson, Chief Commercial Officer (Age 51)
  • James M. Daly, Independent Director (Age 55)
  • Martha J. Demski, Independent Director (Age 64)

Who owns Chimerix stock?

Chimerix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.67%), Schwab Charles Investment Management Inc. (0.43%), Citadel Advisors LLC (0.35%), Granite Investment Partners LLC (0.23%), Russell Investments Group Ltd. (0.17%) and Nationwide Fund Advisors (0.13%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, M Michelle Berrey and Martha J Demski. View Institutional Ownership Trends for Chimerix.

Who bought Chimerix stock? Who is buying Chimerix stock?

Chimerix's stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Citadel Advisors LLC, Russell Investments Group Ltd., Granite Investment Partners LLC and Nationwide Fund Advisors. Company insiders that have bought Chimerix stock in the last two years include Ernest Mario, M Michelle Berrey and Martha J Demski. View Insider Buying and Selling for Chimerix.

How do I buy Chimerix stock?

Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of Chimerix stock can currently be purchased for approximately $4.53.

How big of a company is Chimerix?

Chimerix has a market capitalization of $206.89 million and generates $5.70 million in revenue each year. The biopharmaceutical company earns $-76,390,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 87 workers across the globe.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (CMRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Chimerix (NASDAQ:CMRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.50 (43.49% upside)

Consensus Price Target History for Chimerix (NASDAQ:CMRX)

Price Target History for Chimerix (NASDAQ:CMRX)

Analysts' Ratings History for Chimerix (NASDAQ:CMRX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017FBR & CoReiterated RatingHold$7.00HighView Rating Details
4/28/2017Cowen IncReiterated RatingHold$6.00LowView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/AView Rating Details
8/9/2016J P Morgan Chase & CoReiterated RatingHold$7.00N/AView Rating Details
3/1/2016Citigroup Inc.Reiterated RatingHoldN/AView Rating Details
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00N/AView Rating Details
2/23/2016Barclays PLCDowngradeOverweight -> Equal Weight$12.00 -> $6.00N/AView Rating Details
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00N/AView Rating Details
1/3/2016Brean CapitalDowngradeHoldN/AView Rating Details
1/3/2016Stifel NicolausDowngradeHoldN/AView Rating Details
12/30/2015EmpireReiterated RatingEqual WeightN/AView Rating Details
12/30/2015Janney Montgomery ScottLower Price TargetNeutral$14.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Chimerix (NASDAQ:CMRX)

Earnings by Quarter for Chimerix (NASDAQ:CMRX)

Earnings History by Quarter for Chimerix (NASDAQ CMRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.43)($0.37)$0.81 million$0.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.41)($0.36)$1.28 million$0.68 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.38)$1.56 million$1.08 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.32)$0.89 million$1.98 millionViewListenView Earnings Details
11/7/2016Q3($0.39)($0.37)$1.73 million$0.65 millionViewListenView Earnings Details
8/8/2016Q2($0.51)($0.39)$1.98 million$1.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details
3/6/2015Q414($0.51)($0.52)$1.13 million$1.16 millionViewListenView Earnings Details
11/7/2014Q314($0.41)($0.47)$0.40 million$1.19 millionViewN/AView Earnings Details
8/7/2014Q214($0.46)($0.39)$0.84 million$0.92 millionViewN/AView Earnings Details
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details
11/14/2013Q3($0.38)($0.26)ViewListenView Earnings Details
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chimerix (NASDAQ:CMRX)
2017 EPS Consensus Estimate: ($1.71)
2018 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.42)($0.34)($0.38)
Q2 20172($0.45)($0.41)($0.43)
Q3 20172($0.44)($0.43)($0.44)
Q4 20172($0.49)($0.43)($0.46)
Q1 20181($0.44)($0.44)($0.44)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181$0.48$0.48$0.48
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Chimerix (NASDAQ CMRX)

Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 69.46%
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)

Insider Trades by Quarter for Chimerix (NASDAQ CMRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/28/2016Ernest MarioDirectorSell100,000$4.64$464,000.00View SEC Filing  
9/15/2016John M LeonardDirectorSell5,000$5.03$25,150.00View SEC Filing  
8/29/2016M Michelle BerreyInsiderBuy22,417$4.47$100,203.99View SEC Filing  
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00View SEC Filing  
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72View SEC Filing  
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00View SEC Filing  
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00View SEC Filing  
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00View SEC Filing  
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00View SEC Filing  
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.00View SEC Filing  
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00View SEC Filing  
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.00View SEC Filing  
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Chimerix (NASDAQ CMRX)

Source:
DateHeadline
Chimerix Becomes Oversold (CMRX)Chimerix Becomes Oversold (CMRX)
www.thestreet.com - November 14 at 5:50 PM
Chimerix, Inc. (CMRX) Stock Rating Lowered by Zacks Investment ResearchChimerix, Inc. (CMRX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 13 at 5:55 PM
Chimerix, Inc. (CMRX) Lifted to "Buy" at Zacks Investment ResearchChimerix, Inc. (CMRX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 8:58 PM
Chimerixs (CMRX) CEO Michelle Berrey on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaChimerix's (CMRX) CEO Michelle Berrey on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 9:43 AM
FY2017 EPS Estimates for Chimerix, Inc. (CMRX) Boosted by William BlairFY2017 EPS Estimates for Chimerix, Inc. (CMRX) Boosted by William Blair
www.americanbankingnews.com - November 10 at 7:26 AM
Chimerix, Inc. (CMRX) Cut to Strong Sell at ValuEngineChimerix, Inc. (CMRX) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - November 10 at 12:58 AM
Chimerix, Inc. (CMRX) Issues Quarterly  Earnings ResultsChimerix, Inc. (CMRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 6:55 PM
Chimerix (CMRX) vs. GW Pharmaceuticals PLC (GWPH) Financial ReviewChimerix (CMRX) vs. GW Pharmaceuticals PLC (GWPH) Financial Review
www.americanbankingnews.com - November 9 at 5:28 PM
$1.08 Million in Sales Expected for Chimerix, Inc. (CMRX) This Quarter$1.08 Million in Sales Expected for Chimerix, Inc. (CMRX) This Quarter
www.americanbankingnews.com - November 9 at 2:03 PM
William Blair Weighs in on Chimerix, Inc.s Q1 2018 Earnings (CMRX)William Blair Weighs in on Chimerix, Inc.'s Q1 2018 Earnings (CMRX)
www.americanbankingnews.com - November 9 at 11:46 AM
Chimerix, Inc. to Host Earnings CallChimerix, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 9:21 PM
Chimerix Announces Third Quarter 2017 Financial ResultsChimerix Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 9:21 PM
Chimerix reports 3Q lossChimerix reports 3Q loss
finance.yahoo.com - November 8 at 9:21 PM
Should You Buy Chimerix Inc (CMRX)?Should You Buy Chimerix Inc (CMRX)?
finance.yahoo.com - November 8 at 9:21 PM
Edited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 9:21 PM
Chimerix (CMRX) and Its Rivals Critical ComparisonChimerix (CMRX) and Its Rivals Critical Comparison
www.americanbankingnews.com - November 8 at 5:28 PM
Chimerix to Present at the Stifel 2017 Healthcare ConferenceChimerix to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 10:28 PM
 Analysts Expect Chimerix, Inc. (CMRX) Will Post Earnings of -$0.43 Per Share Analysts Expect Chimerix, Inc. (CMRX) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - November 7 at 1:24 AM
Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017 - GlobeNewswire (press release)Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017 - GlobeNewswire (press release)
globenewswire.com - November 1 at 6:07 PM
Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - November 1 at 6:07 PM
Chimerix, Inc. (CMRX) Set to Announce Earnings on MondayChimerix, Inc. (CMRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
$810,000.00 in Sales Expected for Chimerix, Inc. (CMRX) This Quarter$810,000.00 in Sales Expected for Chimerix, Inc. (CMRX) This Quarter
www.americanbankingnews.com - October 20 at 8:20 AM
Chimerix, Inc. (CMRX) Sees Significant Decrease in Short InterestChimerix, Inc. (CMRX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM
ValuEngine Upgrades Chimerix, Inc. (CMRX) to "Sell"ValuEngine Upgrades Chimerix, Inc. (CMRX) to "Sell"
www.americanbankingnews.com - October 11 at 10:26 PM
Chimerix Stock Sees Short Interest Decline 40%Chimerix Stock Sees Short Interest Decline 40%
www.thestreet.com - October 11 at 6:53 PM
ETFs with exposure to Chimerix, Inc. : October 11, 2017ETFs with exposure to Chimerix, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 6:53 PM
 Brokerages Anticipate Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $810,000.00 Brokerages Anticipate Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $810,000.00
www.americanbankingnews.com - October 1 at 4:00 AM
-$0.43 EPS Expected for Chimerix, Inc. (CMRX) This Quarter-$0.43 EPS Expected for Chimerix, Inc. (CMRX) This Quarter
www.americanbankingnews.com - September 29 at 4:30 PM
Chimerix to Present at Cantor Fitzgerald Global Healthcare ConferenceChimerix to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:05 PM
Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory AffairsChimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs
finance.yahoo.com - September 12 at 5:59 PM
Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory AffairsChimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs
finance.yahoo.com - September 12 at 5:59 PM
ETFs with exposure to Chimerix, Inc. : August 31, 2017ETFs with exposure to Chimerix, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:18 PM
Chimerix, Inc. (CMRX) Expected to Post Quarterly Sales of $810,000.00Chimerix, Inc. (CMRX) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - August 25 at 9:24 AM
Chimerix, Inc. :CMRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Chimerix, Inc. :CMRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:30 PM
Q3 2017 Earnings Forecast for Chimerix, Inc. (NASDAQ:CMRX) Issued By William BlairQ3 2017 Earnings Forecast for Chimerix, Inc. (NASDAQ:CMRX) Issued By William Blair
www.americanbankingnews.com - August 9 at 8:10 AM
Chimerix, Inc. (NASDAQ:CMRX) Announces  Earnings ResultsChimerix, Inc. (NASDAQ:CMRX) Announces Earnings Results
www.americanbankingnews.com - August 8 at 12:28 PM
Edited Transcript of CMRX earnings conference call or presentation 7-Aug-17 12:30pm GMTEdited Transcript of CMRX earnings conference call or presentation 7-Aug-17 12:30pm GMT
finance.yahoo.com - August 8 at 3:48 AM
Chimerix Announces Second Quarter 2017 Financial ResultsChimerix Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 5:45 PM
Chimerix reports 2Q lossChimerix reports 2Q loss
finance.yahoo.com - August 7 at 5:45 PM
 Analysts Expect Chimerix, Inc. (CMRX) Will Announce Earnings of -$0.41 Per Share Analysts Expect Chimerix, Inc. (CMRX) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - August 5 at 7:06 AM
Chimerix, Inc. (NASDAQ:CMRX) Scheduled to Post Earnings on MondayChimerix, Inc. (NASDAQ:CMRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 3 at 8:09 PM
Chimerix to Announce Second Quarter 2017 Financial Results on August 7, 2017Chimerix to Announce Second Quarter 2017 Financial Results on August 7, 2017
finance.yahoo.com - July 31 at 5:16 PM
Chimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.41 Per ShareChimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 13 at 8:28 PM
Chimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside - Seeking AlphaChimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside - Seeking Alpha
seekingalpha.com - May 18 at 4:17 PM
Chimerix reports 4Q lossChimerix reports 4Q loss
us.rd.yahoo.com - March 2 at 4:38 PM
CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsCHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 2 at 4:38 PM
Q4 2016 Chimerix Inc Earnings Release - Before Market OpenQ4 2016 Chimerix Inc Earnings Release - Before Market Open
biz.yahoo.com - March 2 at 7:23 AM
CHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsCHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 4:49 PM
Chimerix (CMRX) Names Randall Lanier as CSO; Roy Ware CMTOChimerix (CMRX) Names Randall Lanier as CSO; Roy Ware CMTO
www.streetinsider.com - January 5 at 9:56 PM
4:30 pm Chimerix appoints Randall Lanier, PhD, as Chief Science Officer4:30 pm Chimerix appoints Randall Lanier, PhD, as Chief Science Officer
us.rd.yahoo.com - January 5 at 9:55 PM

Social Media

Financials

Chart

Chimerix (NASDAQ CMRX) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.